Head-to-head comparison of treatment sequences in advanced pancreatic cancer-Real-world data from the prospective German TPK clinical cohort study

Breast Cancer

Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry

Int J Cancer

Thill M, Zahn MO, Welt A, Nusch A, Zaiss M, Engelken K, Kaltenecker G, Ringwald K, Gratzke K, Dille S, Kruggel L, Jänicke M, Schulz H, Hagen V, Fricker R, Stickeler E, Harbeck N, Wöckel A, Decker T

doi: 10.1002/ijc.35296

SABCS 2024

Breast Cancer

Advancing Breast Cancer Treatment with Elacestrant

SPECIAL REPORT

Breast Cancer

Results of TRODELVY^® real-world data

Genitourinary Cancer

Clinical characteristics and treatment of patients with small cell prostate cancer: analysis of a real-world cohort from an oncology database

Prostate Cancer Prostatic Dis

Eule CJ, Warren A, Molina Kuna E, Robin TP, Gershman B, Kim SP, Flaig TW

doi: 10.1038/s41391-024-00914-z

Lung, Respiratory and Thoracic Cancer

Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer

Lung Cancer

Bauman JR, Liu G, Preeshagul I, Liu SV, Melosky B, Abrahami D, Li B, Thomaidou D, Duncan K, Krulewicz S, Rupp M, Lin JJ

doi: 10.1016/j.lungcan.2024.107919

Gastrointestinal Cancer

Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: A real-world evidence study

Int J Cancer

Slotman E, Pape M, van Laarhoven HWM, Pouw RE, van der Linden YM, Verhoeven RHA, Siesling S, Fransen HP, Raijmakers NJH

doi: 10.1002/ijc.35314

Breast Cancer

Optimizing treatment sequence for inoperable locally advanced breast cancer: Long-term outcomes of surgery first versus neoadjuvant chemotherapy in a real-world setting

Int J Cancer

Liu B, Song Y, Xu Y, Sun Q, Zhou Y, Lin Y

doi: 10.1002/ijc.35140

Lung, Respiratory and Thoracic Cancer

Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective

Lung Cancer

Grit GF, van Geffen E, Malmberg R, van Leeuwen R, Böhringer S, Jm Smit H, Brocken P, Fh Eijsink J, Dronkers E, Gal P, Jaarsma E, Jhm van Drie-Pierik R, Mp Eldering-Heldens A, Machteld Wymenga AN, Gm Mol P, Zwaveling J, Hilarius D

doi: 10.1016/j.lungcan.2024.107950

Lung, Respiratory and Thoracic Cancer

Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study

Lung Cancer

Sugisaka J, Fujimoto D, Tamiya M, Hata A, Matsumoto H, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Kijima T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Saito G, Miura S, Yamaguchi T, Daga H, Sakata S, Yamamoto N, Akamatsu H

doi: 10.1016/j.lungcan.2024.108056

Related content

Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry

Advancing Breast Cancer Treatment with Elacestrant

Results of TRODELVY® real-world data

Clinical characteristics and treatment of patients with small cell prostate cancer: analysis of a real-world cohort from an oncology database

Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer

Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: A real-world evidence study

Optimizing treatment sequence for inoperable locally advanced breast cancer: Long-term outcomes of surgery first versus neoadjuvant chemotherapy in a real-world setting

Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective

Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study

Results of TRODELVY^® real-world data